LONDON--(BUSINESS WIRE)--Technavio has announced its latest pipeline analysis report on cystic fibrosis. The report comprises an in-depth analysis of the pipeline molecules under investigation within the defined data collection period to treat cystic fibrosis.
This report by Technavio presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market during the coming years.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Cystic fibrosis: Market overview
Cystic fibrosis is a genetic defect which leads to the build-up of thick mucus in the lungs. This mucus blocks airways and damages the lungs, which leads to bacterial infection. These bacteria quickly multiply leading to chronic problems. People with cystic fibrosis have high salt levels and the severity of the disease varies from person to person. Regular treatment can reduce the complication and ease the symptoms.
According to a senior analyst at Technavio for infectious and rare diseases research, “Currently there is no cure for the disease, however, it can be treated with medication to ensure long-term survival.”
Cystic fibrosis: Market segmentation
This market research report segments the cystic fibrosis based on therapies employed (monotherapy, combination therapy and unknown), therapeutic modalities (small molecule, gene therapy, recombinant proteins, polysaccharide molecule, monoclonal antibody, ciliated cell therapy, plant derived, and undefined), and RoA (oral, inhalation, intravenous, subcutaneous and unknown).
With respect to RoA, the oral segment accounted for more than 33% of the pipeline comprising of pre-clinical and discovery stage drugs. All the remaining segments comprised of close to 8% of the pipeline.
Based on therapeutic modality, small molecules accounted for over 49% of the pipeline. Small molecules are chemically manufactured active substances that can easily enter cells because of their low molecular weight. These molecules bind with specific biological macromolecules and act as an effector and alter the activity or function of the target cell.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Regulatory Framework
Drug Development Landscape
- Drugs under development
- Indications coverage
Drug Development Strategies
- Therapies employed
- RoA
- Therapeutic modality
- Geographical coverage
Recruitment Strategies
- Recruitment status
- Gender
- Age
- Recruitment volume
Key Companies
- Type of players
- Company Overview
Discontinued or Dormant Molecules
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at media@technavio.com.
